Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

CuII (atsm) inhibits ferroptosis: implications for treatment of neurodegenerative disease.

Southon AA, Szostak K, Acevedo KM, Dent KA, Volitakis I, Belaidi AA, Barnham KJ, Crouch PJ, Ayton S, Donnelly PS, Bush AI.

Br J Pharmacol. 2019 Oct 26. doi: 10.1111/bph.14881. [Epub ahead of print]

PMID:
31655003
2.

Modification of Biodistribution and Brain Uptake of Copper Bis(thiosemicarbazonato) Complexes by the Incorporation of Amine and Polyamine Functional Groups.

Paterson BM, Cullinane C, Crouch PJ, White AR, Barnham KJ, Roselt PD, Noonan W, Binns D, Hicks RJ, Donnelly PS.

Inorg Chem. 2019 Apr 1;58(7):4540-4552. doi: 10.1021/acs.inorgchem.9b00117. Epub 2019 Mar 14.

PMID:
30869878
3.

The social defeat/overcrowding murine psychosocial stress model results in a pharmacologically reversible body weight gain but not depression - related behaviours.

Keenan RJ, Chan J, Donnelly PS, Barnham KJ, Jacobson LH.

Neurobiol Stress. 2018 Sep 21;9:176-187. doi: 10.1016/j.ynstr.2018.09.008. eCollection 2018 Nov.

4.

Targeting metals rescues the phenotype in an animal model of tauopathy.

Sedjahtera A, Gunawan L, Bray L, Hung LW, Parsons J, Okamura N, Villemagne VL, Yanai K, Liu XM, Chan J, Bush AI, Finkelstein DI, Barnham KJ, Cherny RA, Adlard PA.

Metallomics. 2018 Sep 19;10(9):1339-1347. doi: 10.1039/c8mt00153g.

PMID:
30168573
5.

Ablation of tau causes an olfactory deficit in a murine model of Parkinson's disease.

Beauchamp LC, Chan J, Hung LW, Padman BS, Vella LJ, Liu XM, Coleman B, Bush AI, Lazarou M, Hill AF, Jacobson L, Barnham KJ.

Acta Neuropathol Commun. 2018 Jul 5;6(1):57. doi: 10.1186/s40478-018-0560-y.

6.

Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies.

McKenzie-Nickson S, Chan J, Perez K, Hung LW, Cheng L, Sedjahtera A, Gunawan L, Adlard PA, Hayne DJ, McInnes LE, Donnelly PS, Finkelstein DI, Hill AF, Barnham KJ.

ACS Chem Neurosci. 2018 Nov 21;9(11):2731-2740. doi: 10.1021/acschemneuro.8b00161. Epub 2018 Jul 3.

PMID:
29920069
7.

Effect of Structural Modifications to Glyoxal-bis(thiosemicarbazonato)copper(II) Complexes on Cellular Copper Uptake, Copper-Mediated ATP7A Trafficking, and P-Glycoprotein Mediated Efflux.

Acevedo KM, Hayne DJ, McInnes LE, Noor A, Duncan C, Moujalled D, Volitakis I, Rigopoulos A, Barnham KJ, Villemagne VL, White AR, Donnelly PS.

J Med Chem. 2018 Feb 8;61(3):711-723. doi: 10.1021/acs.jmedchem.7b01158. Epub 2018 Jan 8.

PMID:
29232129
8.

A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.

Villemagne VL, Rowe CC, Barnham KJ, Cherny R, Woodward M, Bozinosvski S, Salvado O, Bourgeat P, Perez K, Fowler C, Rembach A, Maruff P, Ritchie C, Tanzi R, Masters CL.

Alzheimers Dement (N Y). 2017 Nov 9;3(4):622-635. doi: 10.1016/j.trci.2017.10.001. eCollection 2017 Nov.

9.

A rigorous method to enrich for exosomes from brain tissue.

Vella LJ, Scicluna BJ, Cheng L, Bawden EG, Masters CL, Ang CS, Willamson N, McLean C, Barnham KJ, Hill AF.

J Extracell Vesicles. 2017 Jul 26;6(1):1348885. doi: 10.1080/20013078.2017.1348885. eCollection 2017.

10.

The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.

Finkelstein DI, Billings JL, Adlard PA, Ayton S, Sedjahtera A, Masters CL, Wilkins S, Shackleford DM, Charman SA, Bal W, Zawisza IA, Kurowska E, Gundlach AL, Ma S, Bush AI, Hare DJ, Doble PA, Crawford S, Gautier EC, Parsons J, Huggins P, Barnham KJ, Cherny RA.

Acta Neuropathol Commun. 2017 Jun 28;5(1):53. doi: 10.1186/s40478-017-0456-2.

11.

Characterization and Identification of Dityrosine Cross-Linked Peptides Using Tandem Mass Spectrometry.

Mukherjee S, Kapp EA, Lothian A, Roberts AM, Vasil'ev YV, Boughton BA, Barnham KJ, Kok WM, Hutton CA, Masters CL, Bush AI, Beckman JS, Dey SG, Roberts BR.

Anal Chem. 2017 Jun 6;89(11):6136-6145. doi: 10.1021/acs.analchem.7b00941. Epub 2017 May 18.

PMID:
28453255
12.

Restoration of intestinal function in an MPTP model of Parkinson's Disease.

Ellett LJ, Hung LW, Munckton R, Sherratt NA, Culvenor J, Grubman A, Furness JB, White AR, Finkelstein DI, Barnham KJ, Lawson VA.

Sci Rep. 2016 Jul 29;6:30269. doi: 10.1038/srep30269.

13.

Synthesis of Oxorhenium(V) and Oxotechnetium(V) Complexes That Bind to Amyloid-β Plaques.

Hayne DJ, White JM, McLean CA, Villemagne VL, Barnham KJ, Donnelly PS.

Inorg Chem. 2016 Aug 15;55(16):7944-53. doi: 10.1021/acs.inorgchem.6b00972. Epub 2016 Jul 26.

PMID:
27459001
14.

Neurological Dysfunction in Early Maturity of a Model for Niemann-Pick C1 Carrier Status.

Hung YH, Walterfang M, Churilov L, Bray L, Jacobson LH, Barnham KJ, Jones NC, O'Brien TJ, Velakoulis D, Bush AI.

Neurotherapeutics. 2016 Jul;13(3):614-22. doi: 10.1007/s13311-016-0427-5.

15.

Gene dysregulation is restored in the Parkinson's disease MPTP neurotoxic mice model upon treatment of the therapeutic drug Cu(II)(atsm).

Cheng L, Quek CY, Hung LW, Sharples RA, Sherratt NA, Barnham KJ, Hill AF.

Sci Rep. 2016 Mar 1;6:22398. doi: 10.1038/srep22398.

16.

Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases.

Mckenzie-Nickson S, Bush AI, Barnham KJ.

Curr Top Med Chem. 2016;16(27):3058-3068. Review.

PMID:
26881708
17.

Amyloid-β Peptide Aβ3pE-42 Induces Lipid Peroxidation, Membrane Permeabilization, and Calcium Influx in Neurons.

Gunn AP, Wong BX, Johanssen T, Griffith JC, Masters CL, Bush AI, Barnham KJ, Duce JA, Cherny RA.

J Biol Chem. 2016 Mar 18;291(12):6134-45. doi: 10.1074/jbc.M115.655183. Epub 2015 Dec 23.

18.

A Functional Role for Aβ in Metal Homeostasis? N-Truncation and High-Affinity Copper Binding.

Mital M, Wezynfeld NE, Frączyk T, Wiloch MZ, Wawrzyniak UE, Bonna A, Tumpach C, Barnham KJ, Haigh CL, Bal W, Drew SC.

Angew Chem Int Ed Engl. 2015 Sep 1;54(36):10460-4. doi: 10.1002/anie.201502644. Epub 2015 Jul 14.

PMID:
26178596
19.

Stabilization of nontoxic Aβ-oligomers: insights into the mechanism of action of hydroxyquinolines in Alzheimer's disease.

Ryan TM, Roberts BR, McColl G, Hare DJ, Doble PA, Li QX, Lind M, Roberts AM, Mertens HD, Kirby N, Pham CL, Hinds MG, Adlard PA, Barnham KJ, Curtain CC, Masters CL.

J Neurosci. 2015 Feb 18;35(7):2871-84. doi: 10.1523/JNEUROSCI.2912-14.2015.

20.

PBT2 inhibits glutamate-induced excitotoxicity in neurons through metal-mediated preconditioning.

Johanssen T, Suphantarida N, Donnelly PS, Liu XM, Petrou S, Hill AF, Barnham KJ.

Neurobiol Dis. 2015 Sep;81:176-85. doi: 10.1016/j.nbd.2015.02.008. Epub 2015 Feb 17.

PMID:
25697105
21.

Small angle X-ray scattering analysis of Cu(2+)-induced oligomers of the Alzheimer's amyloid β peptide.

Ryan TM, Kirby N, Mertens HD, Roberts B, Barnham KJ, Cappai R, Pham Cle L, Masters CL, Curtain CC.

Metallomics. 2015 Mar;7(3):536-43. doi: 10.1039/c4mt00323c.

PMID:
25687761
22.

The N-terminal residues 43 to 60 form the interface for dopamine mediated α-synuclein dimerisation.

Leong SL, Hinds MG, Connor AR, Smith DP, Illes-Toth E, Pham CL, Barnham KJ, Cappai R.

PLoS One. 2015 Feb 13;10(2):e0116497. doi: 10.1371/journal.pone.0116497. eCollection 2015.

23.

Rhenium and technetium complexes that bind to amyloid-β plaques.

Hayne DJ, North AJ, Fodero-Tavoletti M, White JM, Hung LW, Rigopoulos A, McLean CA, Adlard PA, Ackermann U, Tochon-Danguy H, Villemagne VL, Barnham KJ, Donnelly PS.

Dalton Trans. 2015 Mar 21;44(11):4933-44. doi: 10.1039/c4dt02969k.

PMID:
25515141
24.

Synthesis of 2-pyridyl-benzimidazole iridium(III), ruthenium(II), and platinum(II) complexes. study of the activity as inhibitors of amyloid-β aggregation and neurotoxicity evaluation.

Yellol GS, Yellol JG, Kenche VB, Liu XM, Barnham KJ, Donaire A, Janiak C, Ruiz J.

Inorg Chem. 2015 Jan 20;54(2):470-5. doi: 10.1021/ic502119b. Epub 2014 Nov 19.

PMID:
25409492
25.

Peripheral α-defensins 1 and 2 are elevated in Alzheimer's disease.

Watt AD, Perez KA, Ang CS, O'Donnell P, Rembach A, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Faux NG, Masters CL, Villemagne VL, Barnham KJ.

J Alzheimers Dis. 2015;44(4):1131-43. doi: 10.3233/JAD-142286.

PMID:
25408207
26.

Alpha-synuclein oligomers and fibrils originate in two distinct conformer pools: a small angle X-ray scattering and ensemble optimisation modelling study.

Curtain CC, Kirby NM, Mertens HD, Barnham KJ, Knott RB, Masters CL, Cappai R, Rekas A, Kenche VB, Ryan T.

Mol Biosyst. 2015 Jan;11(1):190-6. doi: 10.1039/c4mb00356j. Epub 2014 Oct 29.

PMID:
25352253
27.

High order W02-reactive stable oligomers of amyloid-β are produced in vivo and in vitro via dialysis and filtration of synthetic amyloid-β monomer.

Robb E, Perez K, Hung LW, Masters CL, Barnham KJ, Cherny RA, Bush AI, Adlard PA, Finkelstein DI.

J Alzheimers Dis. 2015;44(1):69-78. doi: 10.3233/JAD-132024.

PMID:
25182735
28.

A commonly used Drosophila model of Alzheimer's disease generates an aberrant species of amyloid-β with an additional N-terminal glutamine residue.

Allan K, Perez KA, Barnham KJ, Camakaris J, Burke R.

FEBS Lett. 2014 Oct 16;588(20):3739-43. doi: 10.1016/j.febslet.2014.08.022. Epub 2014 Aug 27.

29.

β-amyloid in biological samples: not all Aβ detection methods are created equal.

Adlard PA, Li QX, McLean C, Masters CL, Bush AI, Fodero-Tavoletti M, Villemagne V, Barnham KJ.

Front Aging Neurosci. 2014 Aug 13;6:203. doi: 10.3389/fnagi.2014.00203. eCollection 2014. No abstract available.

30.

Anti-Aβ antibody target engagement: a response to Siemers et al.

Watt AD, Crespi GA, Down RA, Ascher DB, Gunn A, Perez KA, McLean CA, Villemagne VL, Parker MW, Barnham KJ, Miles LA.

Acta Neuropathol. 2014 Oct;128(4):611-4. doi: 10.1007/s00401-014-1333-8. Epub 2014 Aug 15. No abstract available.

PMID:
25120193
31.

Biological metals and metal-targeting compounds in major neurodegenerative diseases.

Barnham KJ, Bush AI.

Chem Soc Rev. 2014 Oct 7;43(19):6727-49. doi: 10.1039/c4cs00138a. Epub 2014 Aug 7. Review.

PMID:
25099276
32.

Oral treatment with Cu(II)(atsm) increases mutant SOD1 in vivo but protects motor neurons and improves the phenotype of a transgenic mouse model of amyotrophic lateral sclerosis.

Roberts BR, Lim NK, McAllum EJ, Donnelly PS, Hare DJ, Doble PA, Turner BJ, Price KA, Lim SC, Paterson BM, Hickey JL, Rhoads TW, Williams JR, Kanninen KM, Hung LW, Liddell JR, Grubman A, Monty JF, Llanos RM, Kramer DR, Mercer JF, Bush AI, Masters CL, Duce JA, Li QX, Beckman JS, Barnham KJ, White AR, Crouch PJ.

J Neurosci. 2014 Jun 4;34(23):8021-31. doi: 10.1523/JNEUROSCI.4196-13.2014.

33.

Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

Watt AD, Crespi GA, Down RA, Ascher DB, Gunn A, Perez KA, McLean CA, Villemagne VL, Parker MW, Barnham KJ, Miles LA.

Acta Neuropathol. 2014;127(6):803-10. doi: 10.1007/s00401-014-1290-2. Epub 2014 May 7.

PMID:
24803227
34.

C-terminal peptides modelling constitutive PrPC processing demonstrate ameliorated toxicity predisposition consequent to α-cleavage.

Johanssen VA, Johanssen T, Masters CL, Hill AF, Barnham KJ, Collins SJ.

Biochem J. 2014 Apr 1;459(1):103-15. doi: 10.1042/BJ20131378.

PMID:
24438129
35.

Pathogenic mutations within the hydrophobic domain of the prion protein lead to the formation of protease-sensitive prion species with increased lethality.

Coleman BM, Harrison CF, Guo B, Masters CL, Barnham KJ, Lawson VA, Hill AF.

J Virol. 2014 Mar;88(5):2690-703. doi: 10.1128/JVI.02720-13. Epub 2013 Dec 18.

36.

Quantification of copper binding to amyloid precursor protein domain 2 and its Caenorhabditis elegans ortholog. Implications for biological function.

Leong SL, Young TR, Barnham KJ, Wedd AG, Hinds MG, Xiao Z, Cappai R.

Metallomics. 2014 Jan;6(1):105-16. doi: 10.1039/c3mt00258f.

PMID:
24276282
37.

Structural insights into the interaction of platinum-based inhibitors with the Alzheimer's disease amyloid-β peptide.

Streltsov VA, Chandana Epa V, James SA, Churches QI, Caine JM, Kenche VB, Barnham KJ.

Chem Commun (Camb). 2013 Dec 18;49(97):11364-6. doi: 10.1039/c3cc47326k.

PMID:
24161993
38.

Diagnostic imaging agents for Alzheimer's disease: copper radiopharmaceuticals that target Aβ plaques.

Hickey JL, Lim S, Hayne DJ, Paterson BM, White JM, Villemagne VL, Roselt P, Binns D, Cullinane C, Jeffery CM, Price RI, Barnham KJ, Donnelly PS.

J Am Chem Soc. 2013 Oct 30;135(43):16120-32. doi: 10.1021/ja4057807. Epub 2013 Oct 16.

PMID:
24070589
39.

Therapeutic effects of CuII(atsm) in the SOD1-G37R mouse model of amyotrophic lateral sclerosis.

McAllum EJ, Lim NK, Hickey JL, Paterson BM, Donnelly PS, Li QX, Liddell JR, Barnham KJ, White AR, Crouch PJ.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):586-90. doi: 10.3109/21678421.2013.824000. Epub 2013 Aug 19.

PMID:
23952668
40.

Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes.

Rembach A, Ryan TM, Roberts BR, Doecke JD, Wilson WJ, Watt AD, Barnham KJ, Masters CL.

Biomark Med. 2013 Aug;7(4):641-62. doi: 10.2217/bmm.13.59. Review.

PMID:
23905901
41.

Guanidine hydrochloride denaturation of dopamine-induced α-synuclein oligomers: a small-angle X-ray scattering study.

Pham CL, Kirby N, Wood K, Ryan T, Roberts B, Sokolova A, Barnham KJ, Masters CL, Knott RB, Cappai R, Curtain CC, Rekas A.

Proteins. 2014 Jan;82(1):10-21. doi: 10.1002/prot.24332. Epub 2013 Aug 31.

PMID:
23733394
42.

Mixed ligand Cu2+ complexes of a model therapeutic with Alzheimer's amyloid-β peptide and monoamine neurotransmitters.

Kenche VB, Zawisza I, Masters CL, Bal W, Barnham KJ, Drew SC.

Inorg Chem. 2013 Apr 15;52(8):4303-18. doi: 10.1021/ic302289r. Epub 2013 Mar 28.

PMID:
23537393
43.

Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease.

Rembach A, Faux NG, Watt AD, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, Roberts BR, Perez KA, Li QX, Laws SM, Taddei K, Rainey-Smith S, Robertson JS, Vandijck M, Vanderstichele H, Barnham KJ, Ellis KA, Szoeke C, Macaulay L, Rowe CC, Villemagne VL, Ames D, Martins RN, Bush AI, Masters CL; AIBL research group.

Alzheimers Dement. 2014 Jan;10(1):53-61. doi: 10.1016/j.jalz.2012.12.006. Epub 2013 Mar 13.

PMID:
23491263
44.

Development of a platinum complex as an anti-amyloid agent for the therapy of Alzheimer's disease.

Kenche VB, Hung LW, Perez K, Volitakes I, Ciccotosto G, Kwok J, Critch N, Sherratt N, Cortes M, Lal V, Masters CL, Murakami K, Cappai R, Adlard PA, Barnham KJ.

Angew Chem Int Ed Engl. 2013 Mar 18;52(12):3374-8. doi: 10.1002/anie.201209885. Epub 2013 Feb 10. No abstract available.

PMID:
23401085
45.

Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples.

Watt AD, Perez KA, Rembach A, Sherrat NA, Hung LW, Johanssen T, McLean CA, Kok WM, Hutton CA, Fodero-Tavoletti M, Masters CL, Villemagne VL, Barnham KJ.

Acta Neuropathol. 2013 Apr;125(4):549-64. doi: 10.1007/s00401-013-1083-z. Epub 2013 Jan 25.

PMID:
23354835
46.

Utility of an improved model of amyloid-beta (Aβ₁₋₄₂) toxicity in Caenorhabditis elegans for drug screening for Alzheimer's disease.

McColl G, Roberts BR, Pukala TL, Kenche VB, Roberts CM, Link CD, Ryan TM, Masters CL, Barnham KJ, Bush AI, Cherny RA.

Mol Neurodegener. 2012 Nov 21;7:57. doi: 10.1186/1750-1326-7-57.

47.

Therapeutic redistribution of metal ions to treat Alzheimer's disease.

Crouch PJ, Barnham KJ.

Acc Chem Res. 2012 Sep 18;45(9):1604-11. Epub 2012 Jun 29.

PMID:
22747493
48.

Metals, membranes, and amyloid-β oligomers: key pieces in the Alzheimer's disease puzzle?

Watt AD, Villemagne VL, Barnham KJ.

J Alzheimers Dis. 2013;33 Suppl 1:S283-93. doi: 10.3233/JAD-2012-129017. Review.

PMID:
22699851
49.

The amyloid precursor protein copper binding domain histidine residues 149 and 151 mediate APP stability and metabolism.

Spoerri L, Vella LJ, Pham CL, Barnham KJ, Cappai R.

J Biol Chem. 2012 Aug 3;287(32):26840-53. doi: 10.1074/jbc.M112.355743. Epub 2012 Jun 8.

50.

Modulating metals as a therapeutic strategy for Alzheimer's disease.

Hung LW, Barnham KJ.

Future Med Chem. 2012 May;4(8):955-69. doi: 10.4155/fmc.12.32. Review.

PMID:
22650238

Supplemental Content

Loading ...
Support Center